AMSF has reported Q2 results with the stock slipping 0.9% on Tuesday to $33.98, a muted reaction relative to the split performance seen across its insurance peer group.
The peer picture is the most interesting contrast this week. ERIE fell 4.1% on the day and dropped nearly 9.5% on the week — a sharp move that stands out even in a sector where names gyrated. SIGI and HIG both gained on the week, up 2.5% and 2.8% respectively, while SAFT and RLI drifted modestly lower. AMSF's flat-to-down week puts it in the middle of the cohort, neither a standout beneficiary nor a casualty of whatever macro or sector-specific pressure clipped ERIE so hard. The one prior earnings data point available — Q1, reported in April — saw AMSF drop 1.1% on the day and 2.9% over the following week, so Tuesday's reaction is broadly consistent with that modest-miss template.
The lending market remains indifferent to the print. Availability is extraordinarily loose at roughly 4,961% of short interest — around 50 shares available to lend for every one borrowed — making any squeeze dynamic essentially irrelevant. Short interest edged up 0.7% on Tuesday but is still down about 4.2% on the week at 4.1% of the free float. That monthly build of 60% is worth noting, but the absolute level is modest and the borrow infrastructure to support further short building is clearly there. Cost to borrow has roughly doubled on the week to 0.82%, yet in absolute terms that remains negligible — cheap enough that financing cost is no deterrent to new shorts if they want to add. Options traders are similarly unmoved: the put/call ratio of 0.40 is nearly identical to its 20-day average of 0.41, with a z-score close to zero, indicating no particular directional lean in the derivatives market heading into or out of the print.
The Street view on AMERISAFE has been consistently cautious, with analyst data now roughly three months old and therefore carrying limited freshness. The most recent moves — both from April — saw Truist Securities trim its target to $34 while holding a Hold, and Citizens cut to $45 while keeping a Market Outperform. The mean target of around $36.67 sits only modestly above the current price, implying limited near-term upside in the consensus view. Factor scores underscore the ambivalence: EPS momentum over 30 and 90 days ranks near the bottom of the universe (18th and 8th percentile respectively), while the dividend score of 88 stands out as the one genuine bright spot, and the days-to-cover rank of 62 suggests the short position would take meaningful time to unwind if sentiment shifted. The ORTEX short score has drifted down from around 38.9 in early July to 37.5 now — a mild softening, not a sharp signal.
Institutional ownership is concentrated, with BlackRock holding 17.5% and reporting a modest addition as of June 30. Goldman Sachs Asset Management added around 285,000 shares through late May, bringing its position to 4.5% of shares. Those incremental flows from index-aligned and quant-oriented holders don't constitute a strong conviction signal in either direction — more a function of passive rebalancing than fundamental conviction.
The next data point worth watching is whether the short interest build of the past month continues to unwind following the Q2 print, or whether fresh shorting re-emerges if results disappoint on any reserve development or premium growth metrics that bulls have been citing as the core investment case.
See the live data behind this article on ORTEX.
Open AMSF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
